BioSpace News Archive

Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), reported results for the fiscal 2023 second quarter ended November 27, 2022.

Enzo Biochem, Inc. announced that it has entered into an agreement for Labcorp to acquire the assets of Enzo’s Clinical Laboratory division.

Jounce Therapeutics, Inc. (Nasdaq: JNCE) today announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer are experiencing deep and durable responses based on a pre-planned informal data review.

Gemini BioProducts Holding, Inc. announced the appointment of Gopi Natarajan to the Board of Directors.

Novan, Inc., announced the closing of the issuance and sale in the Company’s previously announced registered direct offering of an aggregate of 5,042,017 shares of its common stock and warrants to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share and associated Common Warrant.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announces that its Chief Executive Officer, Robert Foster, PharmD, PhD, and its Senior Vice President for Clinical Pharmacology and Analytics, Patrick Mayo, PhD, will be presenting during a webinar entitled “How Artificial Intelligence is Changing Drug Discovery” on Thursday, March 23rd at 1:00 p.m. Eastern Time.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2022.

Sensus Healthcare, Inc., the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment, is proud to announce Sensus Cloud.

AVITA Medical, Inc. announced the appointment of Cary Vance to its Board of Directors, effective April 1, 2023.

YS Biopharma Co., Ltd. will become a publicly listed company trading on the Nasdaq Capital Market with its ordinary shares and warrants listed under the new ticker symbols “YS” and “YSBPW”, respectively.